Skip to content

Endovascular Varicose vein Vnus® (endovenous radiofrequency ablation) vs Evlt (endovenous laser therapy) Randomised controlled Trial - EVVERT

A double-blind randomised controlled trial of radiofrequency versus laser treatment of great saphenous varicose veins

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN63135694
Enrollment
100
Registered
2009-01-30
Start date
2008-10-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic great saphenous varicose veins Circulatory System Varicose veins of lower extremities

Interventions

Endovenous laser therapy (EVLT) vs endovenous radiofrequency ablation (VNUS Closure®). Total duration of follow-up: 3 months

Sponsors

St George's, University of London (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Both males and females 2. Primary varicose veins 3. Symptomatic 4. Great saphenous territory

Exclusion criteria

Exclusion criteria: 1. Unable to give informed consent 2. Age 80 3. Recurrent varicosities 4. Pregnant 5. Short saphenous incompetence 6. Tortuous great saphenous vein - not amenable to endovascular treatment 7. Deep vein thrombosis or pulmonary embolism within last year 8. Deep venous insufficiency 9. Warfarinised patient 10. Non-steroidal allergy

Design outcomes

Secondary

MeasureTime frame
1. Pain 1.1. Analogue pain score diary over first week 1.2. Record of analgesia taken. Duration of follow-up: 1 week 2. Bruising. Photographs of legs taken pre-operatively and 1 week post-operatively to assess degree of bruising.

Primary

MeasureTime frame
1. Patency of great saphenous vein as measured by duplex scanning. This will be measured pre-operatively, at one week and three months post-operatively. 2. Health questionnaires, recorded pre-operatively and 3 months post-operatively. 2.1. Specific: Aberdeen Varicose Vein Symptom Severity score (AVVSS) 2.2. Generic: Euroqol EQ-5D

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 27, 2026